MGTX News and Press, MeiraGTx Holdings plc From 08/10/23

2023-08-10 10:50:41 ET MeiraGTx press release ( NASDAQ: MGTX ): Q2 GAAP EPS of -$0.53. Revenue of $3.5M. Cash and cash equivalents were $92.8 million as of June 30, 2023, compared to $115.5 million as of December 31, 2022. For further details see: MeiraGTx GA...

Phase 3 LUMEOS clinical trial of botaretigene sparoparvovec (bota-vec, formerly AAV-RPGR) for the treatment of X-linked retinitis pigmentosa (XLRP) enrollment target has now been surpassed Announced positive clinical data from the completed AQUAx Phase 1 study of AAV2-hAQP1 fo...

LONDON and NEW YORK, Aug. 01, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced a poster presentation at the 2023 American Society of Gene and Cell Therapy (ASGCT) Spotlight on Immuno-oncolog...

LONDON and NEW YORK, July 19, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that after a successful inspection by the Irish Health Products Regulatory Authority (HPRA), it has received a Commercial Manu...

2023-06-23 17:09:25 ET Gainers: Morningstar ( MORN ) +8% . Annexon ( ANNX ) +5% . Cardlytics ( CDLX ) +4% . MeiraGTx Holdings  ( MGTX ) +4% . Lexicon Pharmaceuticals ( LXRX ) +3% . Losers: Lulu's Fashion Lounge ( L...

LONDON and NEW YORK, June 22, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage gene therapy company, today announced it will host a conference call and webcast to present an update on the Company’s AAV-hAQP1 clinical program f...

LONDON and NEW YORK, May 16, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced the Company will exhibit nine poster presentations at the American Society of Gene and Cell Therapy (ASGCT) 2023...

2023-05-11 09:55:38 ET MeiraGTx press release ( NASDAQ: MGTX ): Q1 GAAP EPS of -$0.62 beats by $0.04 . Revenue of $3.33M (-40.9% Y/Y) misses by $1.54M . For further details see: MeiraGTx GAAP EPS of -$0.62 beats by $0.04, revenue of $3.33M misses by $1.54M

Raised approximately $60 million in a private placement in May 2023 with investors consisting of several of the Company’s top shareholders On track for BLA submission of botaretigene sparoparvovec (bota-vec, formerly AAV-RPGR) for the treatment of X-linked retinitis pig...

2023-05-03 09:13:39 ET Gene therapy company MeiraGTx Holdings ( NASDAQ: MGTX ) has agreed to sell ~10.7M shares at $5.75 per share for aggregate gross proceeds of ~$60M. The company intends to use the proceeds to continue to advance its pipeline of gene therapy assets, as well...